Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۰ — حداکثر ۲۰۰۰ • واحد: cells/μL
حداقل ۰ — حداکثر ۷ • واحد: log10 copies/mL
حداقل ۵ — حداکثر ۲۰ • واحد: g/dL
حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/μL
حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L
حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L
حداقل ۰.۵ — حداکثر ۱۰ • واحد: mg/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–25
- Moderate Risk26–50
- High Risk51–75
- Very High Risk76–100
The Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI) calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Combines the Veterans Aging Cohort Study (VACS) Index with the Charlson Comorbidity Index to provide enhanced mortality risk prediction for patients with HIV. This integrated score incorporates HIV-specific biomarkers, general health indicators, and comprehensive comorbidity assessment to estimate 5-year all-cause mortality risk.
Clinical Indication
The Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI) is indicated for bedside clinical practice to support Combines the Veterans Aging Cohort Study (VACS) Index with the Charlson Comorbidity Index to provide enhanced mortality risk prediction for patients with HIV. This integrated score incorporates HIV-specific biomarkers, general health indicators, and comprehensive comorbidity assessment to estimate 5-year all-cause mortality risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
VACS-CCI = [(Linear Predictor + 2.5390222) / 10.6663937] × 100, where Linear Predictor combines VACS Index components (age, CD4, HIV RNA, hemoglobin, FIB-4, eGFR, HCV) with Charlson Comorbidity Index weighted scores
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| sex | string | Yes | Patient sex for accurate eGFR calculation |
| race | string | Yes | Patient race for eGFR calculation (black race adjustment applied) |
| cd4_count | integer | Yes | CD4 T-cell count in cells/μL, primary marker of HIV-related immunodeficiency(cells/μL) |
| hiv_rna_log | float | Yes | HIV-1 RNA viral load in log10 copies/mL, measures viral replication and treatment effectiveness(log10 copies/mL) |
| hemoglobin | float | Yes | Hemoglobin level in g/dL, marker of anemia and overall health status(g/dL) |
| platelets | integer | Yes | Platelet count in ×10³/μL, used in FIB-4 calculation for liver fibrosis assessment(×10³/μL) |
| ast | integer | Yes | Aspartate aminotransferase in U/L, liver enzyme used in FIB-4 calculation(U/L) |
| alt | integer | Yes | Alanine aminotransferase in U/L, liver-specific enzyme used in FIB-4 calculation(U/L) |
| creatinine | float | Yes | Serum creatinine in mg/dL, kidney function marker used for eGFR calculation(mg/dL) |
| hepatitis_c | string | Yes | Hepatitis C virus co-infection status |
| myocardial_infarction | string | Yes | History of myocardial infarction (Charlson Comorbidity Index component) |
| congestive_heart_failure | string | Yes | History of congestive heart failure (Charlson Comorbidity Index component) |
| peripheral_vascular_disease | string | Yes | History of peripheral vascular disease (Charlson Comorbidity Index component) |
| cerebrovascular_disease | string | Yes | History of cerebrovascular disease/stroke (Charlson Comorbidity Index component) |
| dementia | string | Yes | History of dementia (Charlson Comorbidity Index component) |
| chronic_pulmonary_disease | string | Yes | History of chronic pulmonary disease (Charlson Comorbidity Index component) |
| rheumatic_disease | string | Yes | History of rheumatic disease (Charlson Comorbidity Index component) |
| peptic_ulcer_disease | string | Yes | History of peptic ulcer disease (Charlson Comorbidity Index component) |
| mild_liver_disease | string | Yes | History of mild liver disease (Charlson Comorbidity Index component) |
| diabetes | string | Yes | History of diabetes without complications (Charlson Comorbidity Index component) |
| diabetes_complications | string | Yes | History of diabetes with complications (Charlson Comorbidity Index component) |
| hemiplegia | string | Yes | History of hemiplegia or paraplegia (Charlson Comorbidity Index component) |
| renal_disease | string | Yes | History of moderate to severe renal disease (Charlson Comorbidity Index component) |
| any_malignancy | string | Yes | History of any malignancy including leukemia and lymphoma (Charlson Comorbidity Index component) |
| moderate_severe_liver_disease | string | Yes | History of moderate to severe liver disease (Charlson Comorbidity Index component) |
| metastatic_solid_tumor | string | Yes | History of metastatic solid tumor (Charlson Comorbidity Index component) |
| aids | string | Yes | AIDS diagnosis (Charlson Comorbidity Index component) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–25 | Low Risk | Low mortality risk |
| 26–50 | Moderate Risk | Moderate mortality risk |
| 51–75 | High Risk | High mortality risk |
| 76–100 | Very High Risk | Very high mortality risk |
Evidence-Based References (EBM)
- Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care. 2006 Apr;44(4):S52-60. doi: 10.1097/01.mlr.0000208140.93199.44.DOI: 10.1097/01.mlr.0000208140.93199.44
- McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006 Nov 20;24(33):5005-9. doi: 10.1200/JCO.2006.05.7984.DOI: 10.1200/JCO.2006.05.7984
- Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013 Feb 20;27(4):563-72. doi: 10.1097/QAD.0b013e32835c5b67.DOI: 10.1097/QAD.0b013e32835c5b67
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.DOI: 10.1016/0021-9681(87)90171-8